博拓生物(688767.SH)业绩快报：2025年归母净利润4679.57万元，同比减少72.39%

Core Viewpoint - The company reported a significant decline in its financial performance for the fiscal year 2025, with total revenue decreasing by 19.85% compared to the previous year, primarily due to external market factors and increased competition in the industry [1]. Financial Performance Summary - Total revenue for 2025 reached 448 million yuan, a decrease of 19.85% year-on-year [1]. - Operating profit was 50.05 million yuan, down 74.12% from the previous year [1]. - Net profit attributable to the parent company was 46.80 million yuan, reflecting a 72.39% decrease year-on-year [1]. - Net profit excluding non-recurring gains and losses was 24.98 million yuan, a decline of 79.06% compared to the previous year [1]. Factors Affecting Performance - Revenue Impact: The decline in revenue was attributed to multiple factors, including increased tariffs imposed by the U.S. government leading to reduced export sales, intensified competition in the domestic market, and cyclical fluctuations in the respiratory testing product market [1]. - Expense Impact: The company maintained its innovation-driven strategy, focusing on the deep research and quality enhancement of POCT products, which resulted in increased R&D expenses and costs associated with employee stock ownership plans. Additionally, fluctuations in exchange rates and declining financial market deposit rates contributed to reduced financial gains, significantly impacting profits [1]. - Non-Operating Gains and Losses: The previous year's net profit was positively affected by a one-time revenue recognition from a foreign client's order during the pandemic, which did not recur in the current reporting period [2].